Filing Details
- Accession Number:
- 0001609351-17-000069
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-07-07 16:40:19
- Reporting Period:
- 2017-07-05
- Filing Date:
- 2017-07-07
- Accepted Time:
- 2017-07-07 16:40:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1609351 | Spark Therapeutics Inc. | ONCE | Biological Products, (No Disgnostic Substances) (2836) | 462654405 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1631262 | D Jeffrey Marrazzo | C/O Spark Therapeutics, Inc. 3737 Market Street, Suite 1300 Philadelphia PA 19104 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-07-05 | 5,669 | $3.45 | 235,669 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-07-05 | 5,669 | $65.00 | 230,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2017-07-05 | 5,669 | $0.00 | 5,669 | $3.45 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 327,071 | 2024-07-01 | No | 4 | M | Direct |
Footnotes
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016.
- This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter.
Billionaire Hedge Funds
